

















































































Over	 the	 last	 decade,	 the	 main	 theme	 underlying	 my	 research	 in	 Health	
Economics	 has	 been	 to	 estimate	 how	 the	 Value	 for	Money	 of	 breakthrough	
pharmaceutical	 innovation	 evolves	 with	 the	 availability	 of	 new	 clinical	
information.		
In	 2008,	 Prof.	 H.	 Zur	 Hausen	 received	 the	 Nobel	 Prize	 for	 discovering	 the	
cancerogenic	role	of	HPV	that	he	initially	discovered	in	1976.	Following	that,	in	








The	 five	 publications	 included	 for	 examination	 describe	 the	 historical	
contribution	of	my	 research	 to	 the	assessment	of	 the	economic	 value	 to	 the	
payor	 (National	 Health	 System)	 of	 the	 HPV	 immunisation	 following	 the	
availability	 of	 new	 clinical	 information.	 The	 setting	 is	 constant:	 the	 Italian	
population	covered	by	the	NHS.	The	analytical	approach	varies	according	to	the	




girls	 against	 HPV	 would	 be	 beneficial	 and	 cost-effective	 as	 a	 public	 health	
programme	in	Italy.	To	provide	inputs	to	the	model	relevant	to	Italy,	both	terms	
of	the	economic	assessment	were	drawn	from	original	NHS	data	that	were	used	
in	 two	 publications.	 Specifically,	 a	 standardized	 time	 trade-off	 (TTO)	
methodology	was	used	[2]	to	quantify	the	utility	loss	in	health	states	affected	by	








vaccination	 compared	with	 selective	 vaccination	 of	 12-year-old	 girls	 and	 the	
economic	 impact	 of	 immunization	 on	 various	 HPV-induced	 diseases.	 In	 this	
paper,	 a	 dynamic	 Bayesian	Markov	model	 was	 developed	 to	 investigate	 the	
transmission	of	HPV	virus	in	cohorts	of	females	and	males.	As	a	result,	gender-

































economic	 impact	 associated	 with	 a	 quadrivalent	 HPV	 vaccine	 in	 Italy.	
Gynecologic	 Oncology	 ·	 December	 2008.	 DOI:	
10.1016/j.ygyno.2008.09.0312)”	
2) Paper	 2:	 “FS	 Mennini,	 D	 Panatto,	 A	 Marcellusi,	 P	 Cristoforoni,	 R	 De	
Vincenzo,		E	Di	Capua,	G	Ferrandina,	M	Petrillo	T	Sasso,	C	Ricci,	N	Trivellizzi		
A	 Capone,	 G	 Scambia,	 and	 R	 Gasparini.	 Time	 Trade-Off	 Procedure	 for	





of	 preventive	 Health	 Intervention	 and	 On	 time	 Verification	 of	 its	




Cost-Effectiveness	 Analysis	 of	 Universal	 Human	 Papillomavirus	
Vaccination	Using	a	Dynamic	Bayesian	Methodology:	The	BEST	II	Study.	
Value	in	Health,	October	2015.	DOI:	10.1016/j.jval.2015.08.010”	
5) Paper	 5:	 “C.	 Signorelli,	 A.	 Odone,	 V.	 Ciorba,	 P.	 Cella,	 R.A.	 Audisio,	 A.	
Lombardi,	L.	Mariani,	FS.	Mennini,	et	al.,	Human	papillomavirus	9-valent	





















HPV	virus:	 Human	papillomavirus	 (HPV)	 is	 the	cause	of	many	sexually	




HPV	vaccine:	 Human	 papillomavirus	 (HPV)	 vaccines	 prevent	 from	 HPV	
types	 causing	 cervical	 cancer	 as	well	 as	penis,	 anus,	 vulva,	
vagina,	and	oropharynx	cancers.	Available	vaccines	protect	
against	two,	four,	or	nine	types	of	HPV.	
HPV	vaccination:	 Like	 other	 immunizations	 preventing	 viral	 infections,	 HPV	
vaccines	stimulate	an	individual’s	immune	system	to	produce	












in	 the	production	 and	utilisation	of	 health	 and	healthcare.
	 	
Cost-effectiveness:	The	term	cost-effectiveness	compares	the	relative	costs	and	
outcomes	 (effects)	 of	 different	 courses	 of	 action	 and	 has	












The	 main	 argument	 here	 is	 that	 Value	 for	 Money	 of	 breakthrough	
pharmaceutical	 innovation	 changes	 with	 the	 availability	 of	 new	 clinical	
information.	 Health	 Economic	 evaluations	 should	 closely	 monitor	 those	
changes,	to	capture	the	full	value	of	pharmaceutical	innovation	to	society.	
I	was	 fortunate	enough	 to	be	 involved	since	 the	earliest	 stages	 in	 the	Health	
Economic	 assessment	 of	 one	 of	 the	 most	 innovative	 breakthroughs	 of	 the	
century:	the	vaccine	for	the	prevention	of	HPV	virus	infections.		











payor	 (National	 Health	 System)	 of	 the	 HPV	 immunisation	 following	 the	
availability	 of	 new	 clinical	 information.	 The	 setting	 is	 constant:	 the	 Italian	
population	covered	by	the	NHS.	The	analytical	approach	varies	according	to	the	
availability	of	new	inputs	informing	the	economic	models.	A	brief	description	of	
the	 submitted	 evidence	 is	 reported	 below,	with	 the	 aim	 to	 demonstrate	 the	












quantify	 “utility	 loss	 in	 health	 states	 affected	by	HPV-induced	
pathologies	in	Italy”	[2];	






2. HPV	 is	 a	 gender-neutral	 killer:	 cost-effectiveness	 of	 vaccinating	 boys	
against	HPV.	
The	BEST	 II	 study	 [4]	evaluated	both	the	cost-effectiveness	of	universal	
vaccination	 compared	 with	 cervical	 cancer	 screening	 and	 selective,	
female-only	 vaccination	 and	 the	 economic	 impact	 of	 immunization	 on	
various	 HPV-induced	 diseases.	 A	 dynamic	 Bayesian	model	 investigated	










of	 additional	 HPV	 types	 in	 the	 9-valent	 vaccine	 (covering	 against	 nine	
strains	of	 the	virus)	offers	a	 remarkable	potential	 to	expand	protection	
against	HPV	infection.		
The	study	was	 included	in	the	pricing	dossier	for	the	reimbursement	of	
















This	 thesis	 aims	 to	 demonstrate	 how	 the	 Value	 for	Money	 of	 breakthrough	
pharmaceutical	 innovation	 changes	 with	 the	 availability	 of	 new	 clinical	
information.	 Health	 Economic	 evaluations	 should	 closely	 monitor	 those	
changes,	to	capture	the	full	value	of	pharmaceutical	innovation	to	society.	






theoretical	 relevance.	What	 it	matters	 is	 that	 the	only	mode	of	operating	 for	
social	systems,	such	as	the	NHS,	is	the	continuous	evaluation	of	new	information	
related	to	the	observed	impact	of	innovation	on	the	society.	The	autopoiesis	of	
social	 system	 is	 the	 continuous	 reassessment	of	previous	 information	on	 the	
basis	of	new	ones.	Innovation,	in	this	account,	can	only	be	an	ex-post	account:	
“a	 retrospective	 observation	 in	 which	 an	 event	 is	 defined	 as	 something	
innovative	or	transformative”	[2].	









Recently,	 a	 9-valent	 vaccine	 was	 approved,	 which	 protects	 against	 five	
additional	 oncogenic	 HPV	 types,	 providing	 increased	 protection	 [5].	 The	
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introduction	 of	 this	 improved	 vaccine	 affords	 the	 opportunity	 to	 undo	 an	
unintentional	gender	bias	that	has	harmed	HPV	vaccination	efforts.	
In	origin,	due	 to	 the	association	with	cervical	cancer,	HPV	vaccine	 trials	were	
primarily	 based	 on	 females	 and	 consequently,	 the	 vaccine	 was	 reasonably	
approved	 only	 for	 females	 between	 9	 and	 26	 years	 old.	 However,	 this	
administration	schedule	also	 fit	within	an	existing	cultural	narrative	 that	HPV	
was	 a	 ‘woman's	 problem’.	 The	 identification	 of	 HPV	 with	 females,	 and	 its	
subsequent	impact	on	the	setting	of	primary	prevention	strategies,	was	defined	
as	 the	 "feminization	 of	 HPV".	 The	 process	 of	 ‘feminization’	 occurs	 when	 an	








will	 certainly	 involve	 a	 turmoil	 regarding	 guidelines,	 dosage,	 clinical	 practice	
behavior,	 and	 health	 communications,	 new	 strategies	 could	 correct	 gender	
disparities	in	vaccine	delivery.		
HPV	 is	 not	 gender-specific.	 The	 feminization	 of	 HPV	 is	 both	 influenced	 and	






As	 a	 result	 of	 the	 delayed	 diffusion	 of	 scientific	 evidence	 connecting	males,	
cancers	 and	 HPV,	 vaccine	 recommendations	 for	 males	 were	 postponed	 and	
were	 included	 in	 separate	 guidelines.	 Consequently,	 unsettling	
recommendations	 based	 on	 gender	 and	 age	 continue	 to	 exist	 for	 the	 HPV	
vaccine,	with	a	markedly	lower	uptake	among	males.		
The	 deeper	 concern	 is	 that	 the	 feminization	 of	 HPV	 results	 in	 males	 not	




well	 as	 heteronormative	 conventions	 (e.g.,	 ignoring	men	who	 have	 sex	with	
men)	 have	 ultimately	 plagued	 the	 hypothesis	 that	 having	 adequate	 HPV	
vaccination	rates	among	females	would	ultimately	protect	males	through	herd	
immunity.	Indeed,	the	introduction	of	the	vaccine	for	females	only,	biased	the	
cost-effectiveness	question	as	 it	 had	not	 asked	 for	 any	other	 vaccine	before.	
That	is,	the	question	was	framed	as,	"is	it	cost-effective	to	add	male	vaccination	
to	 existing	 female	 vaccination?"	 rather	 than,	 "is	 it	 cost-effective	 to	 vaccinate	
both	 males	 and	 females	 compared	 to	 not	 vaccinating	 anyone?"	 The	 cost-
effectiveness	controversy	around	male	vaccination	is,	in	part,	a	result	of	the	lag	
between	 female	 and	male	 licensure.	 Thus,	 the	diffusion	of	 cost-effectiveness	
evaluations	for	males	continues	to	create	an	unequal	approach	to	vaccine	policy.	
The	last	decade	of	my	research	work	has	been	entirely	dedicated	to	fill	the	gap	
between	 evidence	 generation	 and	 assessment	 of	 the	 social	 value	 of	 HPV	
immunisation	 strategies.	 The	aim	was	 to	maximise	 the	access	 to	vaccination,	
hence	 reducing	 inequalities	 between	 genders,	 sexual	 preferences	 and	
behaviors.	









regarding	 the	most	cost-effective	 immunisation	strategies	 required	 to	 reduce	
the	burden	of	HPV	infections	and	associated	diseases.	The	recognition	that	male	
HPV	 infection	has	a	significant	 impact	on	 the	burden	of	HPV-related	diseases	
justifies	 the	 question	 of	 whether	 males	 should	 be	 or	 not	 included	 in	 the	
vaccination	programme.	
Increasing	 demand	 for	 economic	 and	 epidemiological	 studies	 resulted	 in	 the	
development	 and	 publication	 of	 complex	 statistical	 models	 looking	 at	 the	




emerges	 that	 positions	 on	 gender-neutral	 vaccination	 against	HPV	 (excluding	
the	studies	submitted	for	examination)	have	been	contradictory.		
Two	 studies	 [7,	 8]	 reported	 the	 universal	 vaccination	 against	 HPV	 as	 cost-
effective.	 However,	 as	 pointed	 out	 in	 many	 other	 contributions,	 a	 gender-
neutral	vaccination	schedule	was	also	“possibly	cost-effective”,	“secondary	to	






of	 protection,	 cross-protection,	 duration	 of	 immunisation,	 and	 observation	
period”.	Conversely,	ICER	values	were	decreasing	when	including	a	“larger	set	
of	HPV-induced	diseases	 (such	as	 recurrent	 respiratory	papillomatosis	 -	RPP),	






$50,000	 or	 £30,000),	 may	 depend	 on	 the	 general	 effect	 of	 the	 interaction	
between	the	various	inputs	to	the	model.	As	an	example,	the	highest	ICER	(in	
$2015	values)	observed	among	 the	studies	 included	 in	 the	systematic	 review	
was	 >$200,000.	 This	 value	 was	 driven	 by	 the	 highest	 level	 of	 immunisation	
coverage	observed	 in	 the	 review	 (75%	of	all	 12-26-year-old	women,	a	13-26-
year-old	 women	 catch-up	 cohort	 and	 75%	 of	 all	 12-year-old	 males),	 by	 an	
elevated	(90	to	100%)	adherence	to	a	three-dose	vaccination	schedule,	and	by	
a	relatively	high	vaccine	price	($128	per	vial).	
As	 a	 consequence	 of	 the	 large	 variance	 observed	 in	 the	 use	 of	 different	
economic	inputs	over	the	time,	the	resulted	volatility	implied	in	the	ICER	values	
suggests	 the	 need	 for	 an	 “expiration	 date”	 on	 the	 validity	 of	 the	 normative	








The	 main	 body	 of	 my	 research	 is	 driven	 by	 a	 pragmatic	 approach	 of	 mixed	
methods	 applied	 to	 the	 assessment	 of	 the	 social	 value	 of	 HPV	 vaccination	
strategies.	This	 logic	appeared	best	suited	to	 investigate	the	variety	of	 inputs	
and	 methods	 that	 were	 relevant	 to	 inform	 policy	 decisions	 in	 healthcare,	
allowing	 the	 required	 freedom	 in	 the	 choice	 of	 different	 quantitative	
approaches.	Each	method,	though,	has	its	limitations	and	different	techniques	
can	be	complementary.	


















policy-oriented	 decisions	 about	 whether	 particular	 health	 technologies	
represent	 a	 cost-effective	 use	 of	 healthcare	 resources.	 Typically,	 the	 cost-
effectiveness	of	a	given	set	of	alternative	health	technologies	requires	extensive	
evidence	 that	 is	 not	 available	 from	 a	 single	 source.	 This	 decision-analytic	









sequences	of	events	 that	will	 influence	 the	model’s	 structure,	and	choices	of	
statistical	methods	required	for	deriving	the	model’s	parameters.	 Importantly	
the	absence	of	perfect	 information	for	the	validation	of	a	model	reflects	that	











D	 et	 al.	 Avoiding	 and	 identifying	 errors	 in	 health	 technology	 assessment	 models.	 Health	
Technology	Assessment	2009;	14(25):i-135	













4.	 Model	 checking:	 this	 is	 required	 to	 avoid	 model	 errors	 and	 includes	 the	








current	 research	 into	 the	 social	 value	 of	 HPV	 vaccination	 in	 Italy	 from	 the	
perspective	of	the	Italian	NHS.	They	were	targeted	at	proving	the	main	argument	
of	 my	 research	 that	 the	 Value	 for	 Money	 of	 breakthrough	 pharmaceutical	
innovation	 changes	 with	 the	 availability	 of	 new	 clinical	 information.	 Health	
Economic	evaluations	should	closely	monitor	those	changes,	to	capture	the	full	
value	of	pharmaceutical	innovation	to	society.	
Within	all	 five	papers,	 the	social	 value	of	HPV	 immunisation	was	approached	
















































































































































































































































The	 main	 methodological	 choices	 underpinning	 the	 research	 are	 briefly	
described	below.	
Paper	1:		
Markov	static	model		 Markov	models	 are	 frequently	 used	 to	 evaluate	 the	
cost-effectiveness	 of	 a	 one-time	 decision	 (e.g.	
vaccinate	 or	 not	 to	 vaccinate)	 under	 resource	
constraints.	 Models	 with	 embedded	 decisions	 as	
observed	 in	 sequential	 decision	 problems	 cannot	 be	




Time	Trade-Off	(TTO):	 TTO	 is	widely	 used	 to	 value	 health	 states,	 however,	
there	are	some	limitations.	For	example,	when	people	
are	 asked	 to	 consider	 very	 poor	 states	 of	 health	 –	






Bound	optimisation:	 Bound	 constrained	 optimizations	 are	 problems	
entailing	the	optimization	of	an	objective	function	that	
is	 subject	 to	 bound	 constraints	 on	 the	 values	 of	 the	




Bayesian	models	 Bayesian	 analysis	 refers	 to	 a	 different	 approach	 to	
statistical	inference	in	which	the	purpose	of	collecting	
new	 data	 is	 to	 refine	 the	 estimate	 of	 a	 particular	
quantity	 (often	 a	 probability)	 that	 may	 be	 used	 for	
decision-making.	 This	 contrasts	 with	 traditional	
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‘frequentist’	 statistics	 where	 data	 are	 collected	 to	
reject	or	confirm	a	null	hypothesis	at	a	given	level	of	
statistical	 significance.	 More	 specifically,	 Bayesian	
techniques	are	used	to	“synthesize	information	known	
about	 a	 parameter	 before	 conducting	 a	 study	 with	
new	 data	 from	 the	 study	 to	 estimate	 a	 ‘posterior'	
distribution	for	that	parameter”	[27].	
Cost-effectiveness	 analysis	compares	 the	costs	and	health	effects	of	an	
intervention	 to	 assess	 its	 “value	 for	 money”.	 This	
approach	 is	 used	 to	 assist	 decision-makers	 in	
allocating	limited	healthcare	resources	[28].	
Paper	5:	
Systematic	review	 The	 objective	 of	 systematic	 reviews	 is	 to	 identify,	
critically	 evaluate	 and	 integrate	 the	 findings	 of	
relevant,	high-quality	individual	studies	related	to	one	
or	 more	 research	 questions.	 A	 systematic	 review	 is	
therefore	a	“piece	of	research	in	its	own	right	and,	by	
its	nature,	can	address	much	broader	questions	than	















inform	 policy	 decisions	 in	 Public	 Health,	 such	 as	 the	 optimal	 immunisation	
strategy	to	eradicate	HPV.	By	allowing	the	freedom	to	use	any	of	the	methods,	
techniques	and	procedures	typically	associated	with	quantitative	research,	the	
policy	 recommendation	 moved	 away	 from	 the	 initial	 selective	 strategy	








determine	 the	 health	 impact	 and	 cost-effectiveness	 of	 introducing	 a	
quadrivalent	vaccine	 in	addition	 to	 the	existing	 screening	programme	 for	 the	
23	
	
prevention	 of	 cervical	 cancer	 that	was	 the	main	 indication	 approved.	 In	 this	











health	 benefits	 and	 costs	 respectively.	 Furthermore,	 this	 new	 preventive	
strategy	was	reported	to	be	a	“cost-effective	public	health	programme,	as	the	
cost	 per	 additional	 QALY	 gained	 reached	 €9,569,	 which	 is	 considered	 as	 an	
acceptable	threshold”	[30].	
This	 relatively	 simple	 model	 had	 iconic	 importance	 in	 the	 history	 of	 HPV	
vaccinations.	 Published	 almost	 simultaneously	 with	 this	 study,	 a	 cost-
effectiveness	 analysis	 conducted	 by	 Public	 Health	 England	 made	 the	 same	
recommendations	 for	 the	 HPV	 vaccination	 in	 England	 [31].	 The	 cost-
effectiveness	outcomes	have	been	confirmed	by	hundreds	of	studies	published	
in	the	extant	literature,	employing	a	variety	of	sophisticated	methodologies.	The	

























males,	 thus	 automatically	 considering	 changes	 in	 mixing	 patterns	 and	
population	prevalence	over	time.		







The	 last	 observation	 served	 as	 the	 foundation	 for	 Paper	 5,	 aimed	 to	
“systematically	retrieve,	qualitatively	and	quantitatively	pool,	as	well	as	critically	




method	 named	 PRISMA	 	 (Prepared	 Items	 for	 Systematic	 Reviews	 and	Meta-
Analysis)	and	the	related	guidelines	[22].	











The	 outcomes	 of	 the	 submitted	 body	 of	 research	 established	 the	 cost-
effectiveness	 of	 the	 selective	 HPV	 vaccination,	 posed	 new,	 fundamental	
question	on	how	the	value	for	money	was	assessed,	recognised	the	necessity	of	











address	 the	 issue	of	equality	 in	Public	Health	raised	by	a	selective	 (girls-only)	
vaccination	strategy.	The	principle	of	equity	and	equal	access	to	healthcare	to	
maximize	a	population’s	health	is	a	cornerstone	for	all	health	systems.	Therefore	
the	 universal	 vaccination	 would	 give	 men	 and	 women	 the	 same	 rights	 to	
protection	and	would:	
- protect	 females	and	males	against	many	HPV-related	diseases	









against	 unvaccinated	 female	 or	 male	 partners	 (increased	 risk	
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with	 population	 movements)	 and	 protecting	 the	 most	
vulnerable	people	through	the	prevention	of	genital	warts.	
	














The	 impact	 factor	 (IF)	 is	 a	measure	of	 the	number	of	 citations	 received	by	 a	


















impact	 of	 an	 author,	 an	 article	 or	 a	 publication.	 It	 consists	 of	 “counting	 the	


















synthesis	 among	 multiple	 and	 complementary	 sources	 is	 vital	 to	 produce	
credible	 evidence	 for	 policy	 recommendations	 in	 the	 healthcare	 sector.	
Therefore,	triangulation	refers	to	the	use	of	multiple	sources	of	qualitative	and	
quantitative	 information,	 data	 collection	 and	 analysis	 methods	 for	 obtaining	
valuable	and	complex	findings	or	conclusions.	The	adoption	of	triangulation	can	
strengthen	the	quality	and	credibility	of	the	evidentiary	support	for	findings	and	
recommendations,	 especially	 in	 the	 complex	 field	 of	 analysis	 such	 as	 the	






















development	 of	 quantitative	models	 representative	 of	 the	 Italian	 healthcare	
setting.	This	approach	 justifies	 the	number	of	Authors	acknowledged	 in	each	
published	 paper	 submitted.	 As	 project	 leader,	 my	 first	 contribution	 was	 to	
identify,	 recruit	and	facilitate	the	work	of	 leading	experts.	Although	complex,	





















method	 triangulation.	 I	 directly	 contributed	 to	 the	 methodological	 choices	
underpinning	all	five	submitted	papers,	following	a	clear	trajectory	leading	from	







cervical	 cancer,	 remaining	 life	 expectancy	 and	 quality-adjusted	 life	 years	
(QALYs)”.	 Using	 this	 approach	 the	 total	 direct	 medical	 costs	 related	 to	 the	





Paper	 2	 addressed	 a	 fundamental	methodological	 issue	 of	 cost-effectiveness	
analysis,	the	validity	of	the	method	used	to	elicit	patient	utilities.	This	economic	
























HPV	 transmission	 probabilities,	 partner	 acquisition	 rates,	 and	 population	
prevalence”.	 To	 do	 so,	 all	 parameters	 were	 given	 suitable	 probability	
distributions,	to	reflect	the	state	of	science.	However,	as	a	common	feature	of	
pathogenesis	 in	 human	 medicine,	 most	 parameters	 were	 subject	 to	 a	






conducted	 on	 the	 efficacy,	 immunogenicity,	 and	 safety	 of	 the	 new	 9-valent	
vaccine	against	HPV	 (HPV9),	 as	well	 as	a	 systematic	 search	of	 the	 registered,	
completed,	 active,	 and/or	 ongoing	 clinical	 trials	 (RCTs)	 on	 HPV9.	 The	
methodological	rigour	of	systematic	review	of	the	literature	allowed	to	reduce	
the	heterogeneity	of	the	outcomes,	leading	to	the	collection	of	a	robust	set	of	
inputs,	 including	 efficacy,	 immunogenicity,	 and	 safety	 outcomes,	 which	 will	
32	
	
inform	 the	 next	 generation	 of	 cost-effectiveness	 studies	 of	 gender-neutral	
















across	 countries.	 In	 fact,	 it	 is	well	 acknowledged	 that	“the	patterns	of	 sexual	
behavior	and	the	age	of	sexual	debut	may	vary”	[35].	To	take	into	account	this	





time	 of	 diagnosis;	 a	 histologically	 confirmed	 diagnosis	 of	 CIN2-3;	 a	 recorded	
surgical	 procedure	 of	 hospital	 conisation;	 and	 time	 from	 conisation	 to	
administration	of	questionnaires	78	weeks	(to	avoid	the	potential	impairment	
effect	 of	 recollection	 that	 might	 be	 associated	 with	 a	 stressor	 event)”.	 We	
excluded	 patients	 who	 did	 not	 fully	 complete	 the	 questionnaires	 used	 to	
measure	utilities	and	quality	of	life	and	those	with	an	incomplete	clinical	record.	
The	secondary	data	used	to	inform	the	bound	optimization	model	developed	in	
Paper	 3	 were	 also	 provided	 by	 participating	 Italian	 Healthcare	 trusts.	


















followed	 the	 systematic	 approach	 named	 “PRISMA”	 (Prepared	 Items	 for	
Systematic	 Reviews	 and	 Meta-Analysis)	 guidelines.	 In	 this	 paper,	 published	
studies	were	retrieved	from	the	electronic	databases	Medline,	Embase	and	the	
Cochrane	 Library.	 The	 database	 search	 strategies	 were	 built	 around	 9vHPV-
related	 free-text	 keywords.	 Besides,	 further	 studies	 were	 identified	 and	
downloaded	 from	 reference	 listing	 of	 relevant	 articles	 and	 consultation	with	
experts	in	the	field.	Registered	clinical	trials	were	identified	from	clinical	trials’	


















































































account	 for	 herd	 immunity.	 The	 study	 concluded	 that	 universal	 vaccination	








































This	 study	 aimed	 to	 determine	 the	 health	 impact	 and	 cost-effectiveness	 of	 introducing	 a	
human	papillomavirus	(HPV)	vaccination	programme	with	a	quadrivalent	vaccine	alongside	
the	existing	 cervical	 cancer	 screening	programme	 in	 comparison	 to	 the	current	 context	 in	
Italy.	
METHODS:	
A	 US	Markov	model	 was	 adapted	 to	 the	 Italian	 context,	 assuming	 under	 base	 case	 80%	
vaccine	coverage	rate,	lifetime	duration	of	protection	in	a	cohort	of	girls	aged	12	years	and	
discount	 rates	 of	 1.5%	and	3%	 for	 health	 benefits	 and	 costs,	 respectively,	 and	 estimating	
direct	medical	costs.	
RESULTS:	
The	 HPV	 vaccination	 in	 association	 with	 the	 current	 screening	 programme	 would	 allow	
avoiding	 1432	 cases	 of	 cervical	 cancer	 (-63.3%)	 and	 513	 deaths	 (-63.4%)	 compared	 to	



















off	 (TTO)	 procedure	 to	 quantify	 utility	 loss	 in	 health	 states	 affected	 by	 HPV-induced	
pathologies	in	Italy.	
METHODS:	
This	multicenter,	 retrospective,	 observational,	 cross-sectional	 study	was	 designed	 to	 elicit	
data	on	utilities	in	a	cohort	of	women	with	a	histologically	confirmed	diagnosis	of	high-grade	
cervical	intraepithelial	neoplasias	(CIN2-3).	An	algorithm	for	the	computerized	administration	








perception	of	 their	health	state	was	high	 (mean	 [SD]	EQ-5D	score,	0.93	 [0.10]).	The	mean	
utility	values	were	0.73	(0.22),	0.71	(0.35),	and	0.02	(0.08)	for	CIN2-3,	anogenital	warts,	and	
invasive	 cervical	 cancer,	 respectively.	 Based	 on	 ρ	 values,	 none	 of	 the	 3	 HPV-induced	
pathologies	considered	was	significantly	correlated	with	utility.	Nonsignificant	variability	was	












The	GIOVE	Study	was	aimed	at	 the	achievement	of	 the	allocative	efficiency	of	 the	budget	
allocated	 to	 the	 prevention	 of	 human	 papillomavirus	 (HPV)-induced	 diseases.	 An	 ex-ante	





resources.	 The	 alternatives	 compared	 were	 the	 screening	 programme	 alone	 and	 the	
quadrivalent	immunisation	with	access	to	screening.	A	sensitivity	analysis	was	carried	out	to	
assess	the	uncertainty	associated	with	the	main	inputs	of	the	model.	Subsequently,	a	cohort	






























study	 (Bayesian	modelling	 to	assess	 the	Effectiveness	of	a	vaccination	Strategy	 to	prevent	
HPV-related	 diseases)	 evaluates	 1)	 the	 cost-effectiveness	 of	 immunization	 strategies	






We	 present	 a	 dynamic	 Bayesian	 Markov	 model	 to	 investigate	 transmission	 dynamics	 in	
cohorts	of	 females	and	males	within	a	55-year	 timeframe.	We	assumed	 that	quadrivalent	
vaccination	(against	HPV	16,	18,	6,	and	11)	is	available	for	12-year-old	individuals.	The	model	








Probabilistic	 sensitivity	analysis	 shows	a	 relatively	 large	amount	of	parameter	uncertainty,	
which	interestingly	has,	however,	no	substantial	impact	on	the	decision-making	process.	The	
intervention	 being	 assessed	 seems	 to	 be	 associated	 with	 an	 attractive	 cost-effectiveness	
profile.	
CONCLUSIONS:	















registered,	 completed,	 and	 ongoing	 RCTs.	 We	 retrieved	 and	 screened	 227	 records	 for	
eligibility.	A	total	of	10	publications	reported	on	RCTs'	results	on	9vHPV	and	were	included	in	
the	review.	Sixteen	RCTs	on	9vHPV	have	been	registered	on	RCT	registries.	There	is	evidence	








administration	 in	 subjects	 that	previously	 received	4vHPV	and	9vHPV	efficacy	 in	 regimens	
containing	fewer	than	three	doses.	The	inclusion	of	additional	HPV	types	in	9vHPV	offers	great	
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